

October 12, 2022

**BSE Limited**  
 P.J. Towers,  
 Dalal Street,  
 Mumbai-400001  
 Scrip Code: 530239

**National Stock Exchange of India Limited**  
 "Exchange Plaza",  
 Bandra-Kurla Complex, Bandra (East),  
 Mumbai-400051.  
 Scrip Symbol: SUVEN

Dear Sir/Madam,

**Sub: Outcome of the meeting of the Rights Issue Committee of Board of Directors of Suven Life Sciences Limited ("Company") held today i.e. October 12, 2022.**

**Ref.: Disclosure & Intimation under Regulation 30 and 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations")**

This is further to our intimation dated June 24, 2022 informing approval by the Board of Directors for issue of equity shares by way of a rights issue to the eligible equity shareholders of the Company in accordance with the provisions of Companies Act, 2013 and the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other applicable laws ("**Rights Issue**") and our intimation dated October 07, 2022; we wish to inform you that Members of the Rights Issue Committee of the Board of Directors of the Company, at their meeting held today i.e. on October 12, 2022, **inter-alia, considered and approved the following terms and conditions of the Rights issue:**

- a) **Instrument:** Fully paid-up equity shares of face value of ₹ 1 each ("Equity Shares")
- b) **Total number of Equity Shares and Rights Issue size:** 7,26,91,239 fully paid-up Equity Shares each for amount aggregating to ₹ 399.80/- Crores (Three Hundred and Ninety Nine crore Eighty Lakh).
- c) **Issue Price:** ₹ 55/- per fully paid-up Equity Share [including a premium of ₹ 54/- per Equity Share]
- d) **Outstanding Equity Shares**

Prior to Rights Issue	14,53,82,478 equity shares
Post Rights Issue*	21,80,73,717 equity shares
*assuming full subscription.	

- e) **Rights entitlement ratio:** 1:2 [1 (One) Rights Equity Share for every 2 (Two) fully paid-up Equity Shares held by the Eligible Equity Shareholders of the Company, as on the record date]. If the shareholding of the Eligible Equity Shareholder is 2 (Two) or more, such shareholders will be entitled to at least 1 (One) Equity Share.

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

- f) **ISIN for Rights Entitlement:** INE495B20012
- g) **Other terms of the Rights Issue (including fractional and zero entitlements):** To be included in the Letter of Offer to be filed by the Company.
- h) **Record date:** October 18, 2022 for the purpose of determining the equity shareholders entitled to receive the rights entitlement in the Rights Issue (“Eligible Equity Shareholders”)

The meeting of the Board commenced at 04:00 p.m. and concluded at 04:45 p.m.

This intimation is issued in terms of Regulation 30 and 42 of the SEBI Listing Regulations.

This is for your information as also for the information of your members and the public at large.

Thanking you,

Yours faithfully,

**For Suven Life Sciences Limited**

**Shrenik Soni**  
**Company Secretary**

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)